Popular Trials
Mucolytic Agent
N-acetylcysteine for Lupus
Recruiting0 awardsPhase 2
Syracuse, New York
This trial is a phase II study to test the safety and efficacy of N-acetyl cysteine (NAC) in treating systemic lupus erythematosus (SLE). SLE is a chronic inflammatory disease which often has debilitating and potentially life-threatening consequences. The cause of SLE is unknown and current therapies lack specificity and carry significant side-effects. This study will have two groups of 105 subjects each, with one group continuing the tolerated dosage of NAC and the other group switched to placebo capsules. The study will last 13 months with seven study visits per subject. Each subject will donate approximately 100 ml of blood
Nipocalimab for Lupus Nephritis
Recruiting0 awardsPhase 2
Glendale, Arizona
This trial is testing nipocalimab, a medicine that reduces harmful antibodies, in patients with active Lupus Nephritis, a severe kidney condition caused by lupus. The study will last over a year and will monitor safety and effectiveness.
Janus Kinase (JAK) Inhibitor
Deucravacitinib for Cutaneous Lupus Erythematosus
Recruiting0 awardsPhase 2
Los Angeles, California
This trial is testing a new medication called deucravacitinib to help people with certain types of lupus that aren't well managed by current treatments. The medication works by calming the immune system to reduce skin damage.
Monoclonal Antibodies
Ravulizumab for Lupus Nephritis and IgA Nephropathy
Recruiting0 awardsPhase 2
Los Angeles, California
This trial is testing the safety and effectiveness of a drug called ravulizumab, given through a vein, in patients with specific kidney diseases. The drug aims to reduce kidney damage by blocking part of the immune system.
Iptacopan for Lupus Nephritis
Recruiting0 awardsPhase 2
Phoenix, Arizona
This trial is testing a new medication called iptacopan to see if it can help patients when added to their usual treatments. It targets patients who are already receiving standard care and aims to make their current treatments work better.
Popular Filters
Trials for Systemic Lupus Erythematosus Patients
Memantine for Cognitive Impairment in SLE
Recruiting0 awardsPhase 2
Nashville, Tennessee
This trial is testing memantine, a drug that blocks certain brain receptors, in people with Systemic Lupus Erythematosus (SLE) who have a specific genetic variant. The goal is to see if memantine can safely and effectively reduce cognitive symptoms in these patients. Memantine is used to treat memory and thinking problems and has been investigated for similar issues in SLE patients.
Litifilimab for Lupus
Recruiting1 awardPhase 3
Upland, California
This trial is testing a new drug for Lupus called BIIB059. The goal is to see if it is effective in reducing disease activity, and if it has any other benefits compared to placebo. There are many secondary objectives to this study, including assessing the safety and immunogenicity of the drug.
Litifilimab for Cutaneous Lupus Erythematosus
Recruiting0 awardsPhase 2 & 3
DeBary, Florida
This trial is testing BIIB059, a new medicine that targets specific immune cells, in patients with skin lupus who haven't responded to standard treatments. The goal is to see if it can reduce their skin symptoms by calming down these immune cells.
Trials for SLE Patients
Memantine for Cognitive Impairment in SLE
Recruiting0 awardsPhase 2
Nashville, Tennessee
This trial is testing memantine, a drug that blocks certain brain receptors, in people with Systemic Lupus Erythematosus (SLE) who have a specific genetic variant. The goal is to see if memantine can safely and effectively reduce cognitive symptoms in these patients. Memantine is used to treat memory and thinking problems and has been investigated for similar issues in SLE patients.
Litifilimab for Lupus
Recruiting1 awardPhase 3
Upland, California
This trial is testing a new drug for Lupus called BIIB059. The goal is to see if it is effective in reducing disease activity, and if it has any other benefits compared to placebo. There are many secondary objectives to this study, including assessing the safety and immunogenicity of the drug.
Litifilimab for Cutaneous Lupus Erythematosus
Recruiting0 awardsPhase 2 & 3
DeBary, Florida
This trial is testing BIIB059, a new medicine that targets specific immune cells, in patients with skin lupus who haven't responded to standard treatments. The goal is to see if it can reduce their skin symptoms by calming down these immune cells.
Trials for ANA Positive Patients
Monoclonal Antibodies
Obinutuzumab for Lupus
Recruiting1 awardPhase 3
Fullerton, California
This trial is testing a medication called obinutuzumab in people with active lupus who have specific antibodies in their blood. These patients are already on standard treatments but need more help. The medication works by reducing harmful immune cells that cause inflammation and damage.
Afimetoran for Lupus
Recruiting0 awardsPhase 2
Middleburg Heights, Ohio
This trial is testing a new medication called Afimetoran to help people with active Systemic Lupus Erythematosus (SLE). The goal is to see if it can safely reduce symptoms by calming down the immune system. The study will also provide data on its effectiveness and safety over time.
Monoclonal Antibodies
Subcutaneous Anifrolumab for Lupus
Recruiting1 awardPhase 3
Birmingham, Alabama
This trial is testing an injectable medication called anifrolumab in adults with moderate-to-severe lupus who haven't fully responded to standard treatments. Anifrolumab works by reducing the immune system's attack on the body to help lessen lupus symptoms. It has been approved for the treatment of moderate to severe systemic lupus erythematosus (SLE) based on evidence from various studies.
Monoclonal Antibodies
Belimumab for Lupus
Recruiting1 awardPhase 2
Phoenix, Arizona
This trial is testing a medication called belimumab, given as an injection under the skin, in children with lupus. The goal is to see if it is safe and effective by calming down their overactive immune systems. Belimumab is approved for the treatment of lupus in adults with moderate disease activity.
Janus Kinase (JAK) Inhibitor
Deucravacitinib for Lupus
Recruiting1 awardPhase 3
La Jolla, California
This trial is testing a new medication called deucravacitinib to see if it is safe and effective for people with moderate to severe lupus, a disease where the immune system attacks the body. The medication aims to reduce inflammation by targeting specific enzymes in the immune system.
Trials for Anti-dsDNA Positive Patients
Monoclonal Antibodies
Obinutuzumab for Lupus
Recruiting1 awardPhase 3
Fullerton, California
This trial is testing a medication called obinutuzumab in people with active lupus who have specific antibodies in their blood. These patients are already on standard treatments but need more help. The medication works by reducing harmful immune cells that cause inflammation and damage.
Monoclonal Antibodies
Belimumab for Lupus
Recruiting1 awardPhase 2
Phoenix, Arizona
This trial is testing a medication called belimumab, given as an injection under the skin, in children with lupus. The goal is to see if it is safe and effective by calming down their overactive immune systems. Belimumab is approved for the treatment of lupus in adults with moderate disease activity.
Janus Kinase (JAK) Inhibitor
Deucravacitinib for Lupus
Recruiting1 awardPhase 3
La Jolla, California
This trial is testing a new medication called deucravacitinib to see if it is safe and effective for people with moderate to severe lupus, a disease where the immune system attacks the body. The medication aims to reduce inflammation by targeting specific enzymes in the immune system.
Upadacitinib for Lupus
Recruiting1 awardPhase 3
Flagstaff, Arizona
This trial will assess if upadacitinib is a safe and effective treatment for SLE. 500 people will take part in this trial globally, taking either upadacitinib or a placebo in 3 sub-studies. Regular visits & assessments to check the effect of the treatment will be done.
Phase 3 Trials
Anti-malarial drug
Stopping Hydroxychloroquine for Lupus
Recruiting1 awardPhase 3
Los Angeles, California
This trial is testing if older lupus patients can safely stop taking Hydroxychloroquine, a drug that reduces lupus symptoms but can harm the eyes over time. The study focuses on patients aged 60 and above who have stable disease. Researchers will monitor these patients for an extended period to see if their condition remains stable without the drug.
Monoclonal Antibodies
Obinutuzumab for Lupus
Recruiting1 awardPhase 3
Fullerton, California
This trial is testing a medication called obinutuzumab in people with active lupus who have specific antibodies in their blood. These patients are already on standard treatments but need more help. The medication works by reducing harmful immune cells that cause inflammation and damage.
Litifilimab for Lupus
Recruiting1 awardPhase 3
Upland, California
This trial is testing a new drug for Lupus called BIIB059. The goal is to see if it is effective in reducing disease activity, and if it has any other benefits compared to placebo. There are many secondary objectives to this study, including assessing the safety and immunogenicity of the drug.
Monoclonal Antibodies
Subcutaneous Anifrolumab for Lupus
Recruiting1 awardPhase 3
Birmingham, Alabama
This trial is testing an injectable medication called anifrolumab in adults with moderate-to-severe lupus who haven't fully responded to standard treatments. Anifrolumab works by reducing the immune system's attack on the body to help lessen lupus symptoms. It has been approved for the treatment of moderate to severe systemic lupus erythematosus (SLE) based on evidence from various studies.
Corticosteroid
Obinutuzumab + Standard Therapy for Lupus Nephritis
Recruiting1 awardPhase 3
Birmingham, Alabama
This trial tests if adding obinutuzumab to standard treatments is safe and effective for patients with severe kidney inflammation from lupus. It helps the immune system remove harmful cells and has shown better results in kidney health compared to standard treatments alone.
Trials With No Placebo
Behavioral Intervention
Integrated Care Management for Lupus
Recruiting1 award3 criteria
Boston, Massachusetts
This trialwill study lupus patients at BWH to identify those at high risk of adverse outcomes, and offer intensive care management to reduce avoidable ED visits, hospitalizations and improve high quality care.
Monoclonal Antibodies
Daratumumab for Lupus Nephritis
Recruiting1 awardPhase 2
Rochester, Minnesota
This trial is testing daratumumab, a medication that helps the immune system, in patients with active lupus nephritis. The goal is to see if it can help these patients by reducing kidney damage caused by their disease.
Monoclonal Antibodies
Belimumab for Lupus
Recruiting1 awardPhase 2
Phoenix, Arizona
This trial is testing a medication called belimumab, given as an injection under the skin, in children with lupus. The goal is to see if it is safe and effective by calming down their overactive immune systems. Belimumab is approved for the treatment of lupus in adults with moderate disease activity.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.